Literature DB >> 26809457

The effects anandamide signaling in the prelimbic cortex and basolateral amygdala on coping with environmental stimuli in rats.

Mano Aliczki1, Istvan Barna1, Ibolya Till1, Maria Baranyi2, Beata Sperlagh2, Steven R Goldberg3, Jozsef Haller4.   

Abstract

RATIONALE: Several lines of recent evidence suggest that endocannabinoids affect behavior by influencing the general patterns of challenge responding.
OBJECTIVES: Here, we investigated the brain mechanisms underlying this phenomenon in rats.
METHODS: The anandamide hydrolysis inhibitor URB597 was condensed into the tip of stainless steel cannulae, which were chronically implanted slightly above the prelimbic cortex (PRL) or the basolateral amygdala (BLA), two important regions of coping and endocannabinoid action. Thereafter, we investigated behavioral responsiveness to ambient light level in the elevated plus-maze and conditioned fear tests.
RESULTS: URB597 concentration was ~30 μg/mg protein in target areas; local brain anandamide levels increased threefold, without significant changes in 2-arachidonoylglycerol. High levels of illumination halved the time spent by controls in the open arms of the plus-maze. No similar decrease was observed in rats with URB597 implants in the PRL. High light decreased conditioned fear by 30 % in controls, but not in rats with prelimbic URB597 implants. Unresponsiveness to environmental challenges was not attributable to the anxiolytic effects of anandamide enhancement, as implants induced paradoxical anxiogenic-like effects under low light, which could be explained by effects on stimulus responsiveness rather than by effects on anxiety. URB597 implants targeting the BLA did not affect stimulus responsiveness.
CONCLUSIONS: Our findings show that elevated prelimbic anandamide signaling leads to less environment-dependent (more autonomous) behavioral responses to challenges, which is an attribute of active coping styles. These findings are discussed in light of two emerging concepts of endocannabinoid roles, particularly "emotional homeostasis" and "active coping."

Entities:  

Keywords:  Amygdala; Anandamide; Basolateral amygdala; Coping; Emotional homeostasis; Medial prefrontal cortex; Prelimbic cortex; URB597

Mesh:

Substances:

Year:  2016        PMID: 26809457     DOI: 10.1007/s00213-016-4219-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  51 in total

Review 1.  The endocannabinoid system: emotion, learning and addiction.

Authors:  Fabrício A Moreira; Beat Lutz
Journal:  Addict Biol       Date:  2008-04-16       Impact factor: 4.280

2.  Pre-training anandamide infusion within the basolateral amygdala impairs plus-maze discriminative avoidance task in rats.

Authors:  H Munguba; A Cabral; A H F F Leão; F F Barbosa; G S Izídio; A M Ribeiro; R H Silva
Journal:  Neurobiol Learn Mem       Date:  2011-04-01       Impact factor: 2.877

Review 3.  Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin?

Authors:  F A Moreira; D C Aguiar; A L B Terzian; F S Guimarães; C T Wotjak
Journal:  Neuroscience       Date:  2011-08-27       Impact factor: 3.590

Review 4.  Cannabinoids and anxiety.

Authors:  Fabrício A Moreira; Carsten T Wotjak
Journal:  Curr Top Behav Neurosci       Date:  2010

5.  Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex.

Authors:  T Rubino; N Realini; C Castiglioni; C Guidali; D Viganó; E Marras; S Petrosino; G Perletti; M Maccarrone; V Di Marzo; D Parolaro
Journal:  Cereb Cortex       Date:  2007-10-05       Impact factor: 5.357

Review 6.  Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.

Authors:  Roger G Pertwee
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

7.  Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain.

Authors:  Ermelinda Lomazzo; Laura Bindila; Floor Remmers; Raissa Lerner; Claudia Schwitter; Ulrich Hoheisel; Beat Lutz
Journal:  Neuropsychopharmacology       Date:  2014-08-06       Impact factor: 7.853

8.  Effects of endocannabinoid system modulation on cognitive and emotional behavior.

Authors:  Claudio Zanettini; Leigh V Panlilio; Mano Alicki; Steven R Goldberg; József Haller; Sevil Yasar
Journal:  Front Behav Neurosci       Date:  2011-09-13       Impact factor: 3.558

9.  AAV-Mediated Overexpression of the CB1 Receptor in the mPFC of Adult Rats Alters Cognitive Flexibility, Social Behavior, and Emotional Reactivity.

Authors:  Matthias Klugmann; Anja Goepfrich; Chris M Friemel; Miriam Schneider
Journal:  Front Behav Neurosci       Date:  2011-07-13       Impact factor: 3.558

10.  Insight, distress and coping styles in schizophrenia.

Authors:  Michael Cooke; Emmanuelle Peters; Dominic Fannon; Anantha P P Anilkumar; Ingrid Aasen; Elizabeth Kuipers; Veena Kumari
Journal:  Schizophr Res       Date:  2007-06-11       Impact factor: 4.939

View more
  3 in total

1.  Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity.

Authors:  Amir Segev; Nachshon Korem; Tomer Mizrachi Zer-Aviv; Hila Abush; Rachel Lange; Garrett Sauber; Cecilia J Hillard; Irit Akirav
Journal:  Neuropsychopharmacology       Date:  2018-06-27       Impact factor: 7.853

Review 2.  Prefrontal endocannabinoids, stress controllability and resilience: A hypothesis.

Authors:  Nicholas B Worley; Matthew N Hill; John P Christianson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-04-07       Impact factor: 5.067

3.  Metabotropic Glutamate Receptor 5 in the Medial Prefrontal Cortex as a Molecular Determinant of Pain and Ensuing Depression.

Authors:  Geehoon Chung; Sang Jeong Kim; Sun Kwang Kim
Journal:  Front Mol Neurosci       Date:  2018-10-08       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.